Conference Coverage: ESMO 2023 – Focus on Genitourinary (GU) Malignancies

Impact of recent ESMO data on clinical practice and therapy guidance in GU cancers

November 1, 2023
Daniel Petrylak, MD, Yale, Aptitude Health


Daniel Petrylak, MD

Yale Cancer Center, New Haven, CT, USA

Faculty Members

Scott Tagawa, MD, FACP, FASCO
Weill Cornell Medicine, New York, NY, USA

Leonard G. Gomella, MD, FACS
Thomas Jefferson University, Philadelphia, PA, USA

Robert Dreicer, MD, MACP, FASCO
University of Virginia Cancer Center, Charlottesville, VA, USA

Susan Slovin, MD, PhD
Memorial Sloan Kettering Cancer Center, New York, NY, USA

Karim Fizazi, MD, PhD
Gustave Roussy Institute, Villejuif, France

Manuela Schmidinger, MD
Medical University of Vienna, Austria

Sample Report

Start discovering the insights

View Report


  • Metastatic Castration-Resistant Prostate Cancer
  • Hormone-Sensitive Prostate Cancer
  • Bladder Cancer Part 1 – NMIBC and MIBC
  • Bladder Cancer Part 2 – Therapies for Metastatic Disease
  • Clear Cell Renal Cell Carcinoma

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.